Roche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed with Ionis, after a pre-planned review by independent experts. The companies had been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback